OncoVanta Therapeutics
Biotechnology Research • • 1-10 Employees
Company overview
| Headquarters | XX |
| Website | |
| NAICS | 541714 |
| Employees | 1-10 |
Key Contact at OncoVanta Therapeutics
Roman Owens
Founder & Chief Executive Officer | OncoVanta Therapeutics, Inc
About OncoVanta Therapeutics
OncoVanta Therapeutics is a biotechnology company pioneering next-generation immunotherapies targeting mutant p53, the most frequently altered gene in human cancers. More than 50% of all tumors harbor TP53 mutations, yet no approved therapies directly address this major unmet medical need. Leveraging NIH-derived TCR (T- cell receptor) assets and cutting edge cell therapy platforms, OncoVants is advancing a novel pipeline of TCR-based adoptive cell therapies designed to selectively target hotspot p53 mutations in solid tumors. Our Mission is clear; turn breakthrough science into life-saving medicines for patients with hard-to treat cancers. Specialties: • Adoptive Cell Therapy (ACT) • T Cell Receptor (TCR) Engineering • p53 Mutant Oncology • Immuno-Oncology (I/O) • Translational Research &; Development • Biotech Partnerships & Licensing
OncoVanta Therapeutics revenue & valuation
| Annual revenue | $85,555 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $273,776 |
| Total funding | No funding |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
OncoVanta Therapeutics has 1 employees across 1 departments.
Departments
Number of employees
Funding Data
OncoVanta Therapeutics has never raised funding before.
Canada
Spain
United Kingdom
Frequently asked questions
4.8
40,000 users
